LAUSR

daily and dupilumab 300 mg every 4 weeks. The followup MRI examination interval is 3 months. To our knowledge, this is the first report of dupilumab combined with corticosteroid in the treatment of EF. Our patient improved slowly with methylprednisolone monotherapy but recovered rapidly after starting dupilumab treatment, which supports that Type 2 innate immunity might be related to EF and that Th2 cytokines play important roles in EF. However, the definite role and efficacy of dupilumab in EF treatment is still uncertain. Further study and case series are needed to establish the efficacy of using dupilumab either as monotherapy or apart of combination therapy for EF.